These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1129 related articles for article (PubMed ID: 20095819)

  • 1. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders.
    Wang X; Klann PJ; Wiedtke E; Sano Y; Fischer N; Schiller L; Elfert A; Güttsches AK; Weyen U; Grimm D; Vorgerd M; Bayer W
    Front Immunol; 2024; 15():1450858. PubMed ID: 39399494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
    Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse IgG subclass responses to adeno-associated virus infection and vector administration.
    Murphy SL; Li H; Mingozzi F; Sabatino DE; Hui DJ; Edmonson SA; High KA
    J Med Virol; 2009 Jan; 81(1):65-74. PubMed ID: 19031458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors.
    Xicluna R; Avenel A; Vandamme C; Devaux M; Jaulin N; Couzinié C; Le Duff J; Charrier A; Guilbaud M; Adjali O; Gernoux G
    Hum Gene Ther; 2024 May; 35(9-10):355-364. PubMed ID: 38581431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of naturally-occurring humoral immunity to AAV in sheep.
    Tellez J; Van Vliet K; Tseng YS; Finn JD; Tschernia N; Almeida-Porada G; Arruda VR; Agbandje-McKenna M; Porada CD
    PLoS One; 2013; 8(9):e75142. PubMed ID: 24086458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.
    Monteilhet V; Saheb S; Boutin S; Leborgne C; Veron P; Montus MF; Moullier P; Benveniste O; Masurier C
    Mol Ther; 2011 Nov; 19(11):2084-91. PubMed ID: 21629225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.
    Gao GP; Alvira MR; Wang L; Calcedo R; Johnston J; Wilson JM
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11854-9. PubMed ID: 12192090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
    Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
    J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.
    Rutledge EA; Halbert CL; Russell DW
    J Virol; 1998 Jan; 72(1):309-19. PubMed ID: 9420229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
    Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.